Fertility startup Inito has successfully closed a $29 million Series B funding round, bringing its total capital raised to approximately $45 million. The substantial investment will accelerate the development of AI-engineered antibodies, a groundbreaking technology poised to revolutionize at-home health diagnostics. Inito plans to leverage these advanced antibodies to introduce new types of tests, enhance the accuracy of its existing offerings, and expand its platform beyond fertility tracking into a comprehensive at-home hormone monitoring system.
Inito's Impact on Fertility Tracking
Since launching its initial fertility monitor in 2021, Inito has empowered women to quantitatively track key fertility hormones from the comfort of their homes. Unlike standard at-home ovulation tests that typically predict fertile days by monitoring estrogen and Luteinizing Hormone (LH), Inito's innovative test strips measure estrogen, LH, progesterone (PdG), and Follicle-Stimulating Hormone (FSH) simultaneously. The platform's sophisticated AI models then interpret these hormone levels, revealing fertility patterns, pinpointing fertile windows, and crucially, confirming ovulation through PdG measurement. This comprehensive approach has resonated with users, with Inito analyzing over 30 million fertility hormone data points since its inception.
Expanding Beyond Fertility
Driven by a strong belief that healthcare should originate at home, Inito is now strategically evolving its at-home health diagnostics platform. The company aims to transition from solely a fertility tracker into a broader, more versatile at-home health diagnostics and hormone monitoring solution. This expansion will see Inito's technology applied to a wider range of health needs, including pregnancy progression, menopause, and other endocrine markers like testosterone.
The Power of AI-Designed Antibodies
A significant portion of the new funding will be dedicated to advancing Inito's pioneering work in AI-engineered antibodies. These antibodies are central to the company's vision for next-generation at-home tests, promising superior accuracy and the ability to detect a broader array of biomarkers. Traditionally, antibodies used in diagnostic tests are cultivated in animals and then manually screened in labs—a process that is often slow, costly, and limited in sensitivity for many at-home applications. Inito's approach radically transforms this.
"We predict how proteins fold in 3D, design synthetic antibodies using AI, and test millions of variants virtually before making a single one in the lab," explained Inito co-founder and CTO Varun A Venkatesan. "This produces antibodies that are far more sensitive, consistent, and stable than anything developed through traditional methods."
This 'software-like' development process for antibodies is already yielding promising results in Inito's R&D wet-lab, paving the way for unprecedented diagnostic capabilities.
Redefining At-Home Diagnostics
The implications of this AI-driven antibody technology extend far beyond simply adding new tests. Inito co-founder and CEO Aayush Rai articulated the company's ambitious 'endgame':
"The real vision is bigger than adding new tests. The endgame is to redefine diagnostics altogether. If you want to understand what’s happening inside your body at every life stage and health need, you shouldn’t be limited by clinic appointments, lab schedules, or rigid testing systems. You should be able to measure, track, and get insights about your body from home, with lab-grade confidence."
Rai emphasized that Inito's long-term roadmap is expansive, aiming to measure and interpret the full spectrum of hormones that influence health throughout a person's lifetime, all powered by their distinctive AI antibodies and imaging technology.
Funding and Global Growth
Beyond technological development, Inito plans to allocate part of the new capital to scale its manufacturing operations and expand its global footprint. This strategic move aims to meet the escalating demand across the United States and penetrate new international markets. The Series B funding round was co-led by Bertelsmann India Investments and Fireside Ventures. Earlier investments included $6 million led by Fireside Ventures and $9 million from Y Combinator, former Nurx CEO Varsha Rao, and a consortium of physicians and family offices, culminating in the reported total funding of approximately $45 million.
